Akari Therapeutics (AKTX) Notes Payables (2012 - 2026)

Akari Therapeutics has disclosed Notes Payables across 4 years of filings, most recently posting $49000.0 for Q1 2026.

• Notes Payables for Q1 2026 came in at $49000.0, down 78.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $49000.0 (down 78.51% YoY), and the FY2025 annual result was $81000.0, down 87.71% from the prior year.
• Notes Payables came in at $49000.0 for Q1 2026 at Akari Therapeutics, down from $81000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $659000.0 in Q4 2024 to a low of $49000.0 in Q1 2026.
• The 3-year median for Notes Payables is $188500.0 (2025), against an average of $232333.3.
• Across the five-year window, Notes Payables plunged 87.71% in 2025 and sank 78.51% in 2026, its largest moves.
• Akari Therapeutics' Notes Payables stood at $659000.0 in 2024, then slumped by 87.71% to $81000.0 in 2025, then plunged by 39.51% to $49000.0 in 2026.
• The last three Notes Payables figures came in at $49000.0 (Q1 2026), $81000.0 (Q4 2025), and $198000.0 (Q3 2025), per Business Quant data.